From X to Rx: Confronting Real World Obstacles to Buprenorphine Prescribing
This coursel course will address the challenges of managing patients on buprenorphine in different practice settings
Experts in the field will discuss :
- successfully navigating DEA visits,
- obtaining reimbursement,
- managing inductions,
- urine drug testing,
- preventing diversion.
Participants will be provided with a toolkit which they can begin to use immediately to jump start their own buprenorphine practice. There will be two follow-up webinars after the workshop to field questions about systems and clinical care as providers implement treatment.
It will not provide a waiver for those who do not have one.
PRICE/PURCHASE -- $125
You must sign in or register register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and choose your purchase option (member/non-member) and click "Add to Cart."
PHYSICIANS: The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 3.5 AMA/PRA Category 1 Credits™ for completing the Review Course.
Continuing education credit is also available for nurses, psychologists, pharmacists, physician assistants, therapists, and drug abuse counselors.
This workshop is designed for those with a buprenorphine waiver who are not yet fully utilizing it in their practice. Other clinicians who work with, or are considerind working with patients on buprenorphine are also encouraged to participate.
At the end of this activity participants should be able to
- Address difficult issues in induction of patients on buprenorphine
- Decide what formulation is best for different patients
- Utilize practice tools provided to begin utilizing buprenorphine in office-based treatment of opioid dependence
David Kan, MD: Workshop Chair, Chair, CSAM Committee on Opioids, General, Addiction and Forensic Psychiatry, Walnut Creek, CA
Ken Saffier, MD: Family and addiction medicine; Contra Costa Regional Medical Center and Health Centers Family Medicine Residency: Clinical Professor, Department of Family and Community Medicine, University of California, San Francisco.
Karen Miotto, MD: Professor in the Department of Psychiatry and Behavioral Sciences at UCLA; Medical Director of the UCLA Addiction Medicine Service and the Medical Director of the Opioid Treatment Program at the Downtown Los Angeles Ambulatory Care VAMC
Matthew Torrington, MD: Medical Director at the Common Ground/End Dependence Free Clinic in Santa Monica, California; Principal Investigator and Research Physician with Friends Research Institute in Torrance, CA; Addiction Medicine Research Physician with the UCLA Integrated Substance Abuse Programs (ISAP) in Los Angeles; Primary Addiction Medicine Physician/Consultant at Avalon Malibu in Malibu; Consulting Addiction Medicine Physician at Cri Help in North Hollywood.
Margaret Haglund, MD: Cedars Sinai Medical Center, Los Angeles
Soraya Azari, MD: Assistant Professor, UCSF Department of Medicine
Dr. Torrington reports the following relevant financial relationships:
- Current speaker Orexo pharmaceuticals
- Current speaker and consultant, BDSI pharmaceuticals
- Current consultant, Braeburn Pharmaceuticals
- Former consultant and speaker Reckitt Benkiser
Conference Planners have reviewed his presentation and have found it free of commercial bias.
None of the other speakers planners have reported any relevant financial relationships.
- 3.50 AMA Category 1